Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials

Phase 3 ◽

Sustained Improvement

27389 Rapid and sustained improvement in itch in children aged 6–11 years with severe atopic dermatitis (AD) treated with dupilumab: Analysis from the LIBERTY AD PEDS phase 3 trial

10.1016/j.jaad.2021.06.576 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB140

Author(s):

Amy S. Paller ◽

Elaine C. Siegfried ◽

Gil Yosipovitch ◽

Jonathan I. Silverberg ◽

Jashin J. Wu ◽

...

Keyword(s):

Atopic Dermatitis ◽

Phase 3 ◽

Sustained Improvement

27082 Upadacitinib in moderate-to-severe atopic dermatitis: Combined safety analysis of phase 3 studies (Measure Up 1, Measure Up 2, and AD Up)

10.1016/j.jaad.2021.06.534 ◽

2021 ◽

Vol 85 (3) ◽

pp. AB129

Author(s):

Emma Guttman-Yassky ◽

Alan D. Irvine ◽

Jonathan I. Silverberg ◽

Kim A. Papp ◽

Amy S. Paller ◽

...

Keyword(s):

Atopic Dermatitis ◽

Safety Analysis ◽

Phase 3

Dupilumab in Moderate-to-Severe Atopic Dermatitis With or Without Comorbid Asthma: Pooled Analysis of 2 Randomized Phase 3 Trials (LIBERTY AD SOLO 1 & 2)

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2017.12.420 ◽

2018 ◽

Vol 141 (2) ◽

pp. AB132

Author(s):

Mette Deleuran ◽

Emma Guttman-Yassky ◽

Kulli Kingo ◽

Neil M.H. Graham ◽

Gianluca Pirozzi ◽

...

Keyword(s):

Atopic Dermatitis ◽

Pooled Analysis ◽

Phase 3

Dupilumab in Moderate-to-Severe Atopic Dermatitis With or Without Comorbid Food Allergy: Pooled Analysis of 2 Randomized Phase 3 Trials (LIBERTY AD SOLO 1 & 2)

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2017.12.418 ◽

2018 ◽

Vol 141 (2) ◽

pp. AB131

Author(s):

Eric L. Simpson ◽

Jean-Philippe Lacour ◽

Jonathan I. Silverberg ◽

Margitta Worm ◽

Andreas Wollenberg ◽

...

Keyword(s):

Atopic Dermatitis ◽

Food Allergy ◽

Pooled Analysis ◽

Phase 3

ESDR084 - Herpes virus infections amongst moderate to severe atopic dermatitis patients treated with baricitinib: an integrated analysis of phase 3 trials

10.26226/morressier.61081ff8bc981037240fe3dd ◽

2021 ◽

Author(s):

Thomas Werfel

Keyword(s):

Atopic Dermatitis ◽

Herpes Virus ◽

Integrated Analysis ◽

Virus Infections ◽

Phase 3 ◽

Herpes Virus Infections ◽

Herpès Virus

Dupilumab in Adolescents With Moderate-to-Severe Atopic Dermatitis and a History of Allergic Rhinitis: Subgroup Analysis From a Phase 3 Trial

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2019.12.267 ◽

2020 ◽

Vol 145 (2) ◽

pp. AB191

Author(s):

Lawrence Sher ◽

Weily Soong ◽

Paola Mina-Osorio ◽

Randy Prescilla ◽

Zhen Chen ◽

...

Keyword(s):

Allergic Rhinitis ◽

Atopic Dermatitis ◽

Subgroup Analysis ◽

Phase 3 ◽

History Of

15054 Impact of baricitinib on patient-reported skin symptoms, itch, and quality of life in adult patients with moderate to severe atopic dermatitis and an inadequate response to topical therapies from phase 3 trials BREEZE-AD1 and BREEZE-AD2

10.1016/j.jaad.2020.06.198 ◽

2020 ◽

Vol 83 (6) ◽

pp. AB28

Author(s):

Peter Lio ◽

Audrey Nosbaum ◽

Tracy Cardillo ◽

Amy DeLozier ◽

Margaret Gamalo ◽

...

Keyword(s):

Quality Of Life ◽

Atopic Dermatitis ◽

Adult Patients ◽

Inadequate Response ◽

Phase 3 ◽

Skin Symptoms ◽

Patient Reported

16405 Abrocitinib treatment in patients with moderate to severe atopic dermatitis: Consistency of efficacy responses from randomized, controlled phase 3 and phase 2b clinical trials

10.1016/j.jaad.2020.06.336 ◽

2020 ◽

Vol 83 (6) ◽

pp. AB62

Author(s):

Eric L. Simpson ◽

Melinda Gooderham ◽

Brett King ◽

Susan C. Taylor ◽

David Rosmarin ◽

...

Keyword(s):

Clinical Trials ◽

Atopic Dermatitis ◽

Phase 3 ◽

Randomized Controlled

Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS

10.1016/j.jaad.2020.02.060 ◽

2020 ◽

Vol 82 (6) ◽

pp. 1328-1336 ◽

Cited By ~ 9

Author(s):

Jonathan I. Silverberg ◽

Gil Yosipovitch ◽

Eric L. Simpson ◽

Brian S. Kim ◽

Jashin J. Wu ◽

...

Keyword(s):

Atopic Dermatitis ◽

Treatment Results ◽

Phase 3 ◽

Adolescents And Adults

Use of Topical Corticosteroids with Tralokinumab in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.4.supp.99 ◽

2020 ◽

Vol 4 (6) ◽

pp. s99

Author(s):

Jonathan Silverberg ◽

Andrew Pink ◽

Christina Olsen ◽

Stephan Weidinger

Keyword(s):

Atopic Dermatitis ◽

Adult Patients ◽

Phase 3 ◽

Topical Corticosteroids

Abstract not available.